Search Results

You are looking at 1 - 10 of 118 items for :

  • "pituitary tumour" x
  • All content x
Clear All
Open access

Paraskevi Xekouki, Emily J Lodge, Jakob Matschke, Alice Santambrogio, John R Apps, Ariane Sharif, Thomas S Jacques, Simon Aylwin, Vincent Prevot, Ran Li, Jörg Flitsch, Stefan R Bornstein, Marily Theodoropoulou, and Cynthia L Andoniadou

, clear cell renal cell carcinoma (ccRCC), pancreatic carcinoma, oesophageal squamous cell carcinoma, urothelial carcinoma of the bladder and skin basal cell carcinoma ( Zanconato et al. 2016 ). Pituitary tumours account for 10–15% of intracranial

Free access

Ben C Whitelaw

How and when to use temozolomide to treat aggressive pituitary tumours Temozolomide is an oral chemotherapy which has an established role in treating glioblastoma multiforme (GBM) and has since 2006 been used to treat aggressive and malignant

Free access

W E Farrell

Pathogenesis of pituitary tumours Pituitary adenomas Pituitary adenomas are common intracranial neoplasms, comprising 10–15% of diagnosed brain tumours ( Kovacs & Hovarth 1987 ). Tumours may arise from any of the

Free access

M Muşat, M Korbonits, B Kola, N Borboli, M R Hanson, A M Nanzer, J Grigson, S Jordan, D G Morris, M Gueorguiev, M Coculescu, S Basuand, and A B Grossman

Introduction Pituitary tumours account for 10–15% of all intracranial neoplasms. Despite extensive research, the pathogenesis of the majority of pituitary adenomas remains to be clarified. Deregulation of various cell-cycle pathways

Free access

Dorota Dworakowska and Ashley B Grossman

Introduction Pituitary tumours represent approximately 10–15% of intracranial tumours. Most of them are non-invasive, showing slow growth and remaining within the sella and/or displacing the surrounding tissues; however, up to 25–55% of

Free access

B Shan, J Gerez, M Haedo, M Fuertes, M Theodoropoulou, M Buchfelder, M Losa, G K Stalla, E Arzt, and U Renner

Introduction RSUME is a small RWD-domain containing protein that was recently cloned from lactosomatotroph GH3 rat pituitary tumour cells overexpressing the cytokine signal transducing protein gp130 ( Carbia-Nagashima et al . 2007 ). These cells

Free access

M Principe, M Chanal, V Karam, A Wierinckx, I Mikaélian, R Gadet, C Auger, V Raverot, E Jouanneau, A Vasiljevic, A Hennino, G Raverot, and P Bertolino

Introduction Pituitary tumour is the second most common primary brain tumour in adults ( Asa & Ezzat 2002 , Asa et al . 2017 ). Pituitary tumours are considered as benign, yet their deleterious effects are multiple, ranging from visual

Free access

Antônio Ribeiro-Oliveira Jr, Giulia Franchi, Blerina Kola, Paolo Dalino, Sérgio Veloso Brant Pinheiro, Nabila Salahuddin, Madalina Musat, Miklós I Góth, Sándor Czirják, Zoltán Hanzély, Deivid Augusto da Silva, Eduardo Paulino Jr, Ashley B Grossman, and Márta Korbonits

Introduction Pituitary tumours are very common neoplasms, with a reported prevalence of 17% in the general population, and they constitute 10% of intracranial neoplasms ( Asa & Ezzat 2002 , Ezzat et al . 2004 ). Although these tumours cause

Free access

C Schaaf, B Shan, M Buchfelder, M Losa, J Kreutzer, W Rachinger, G K Stalla, T Schilling, E Arzt, M J Perone, and U Renner

secretion in the lactosomatotroph GH3 rat pituitary tumour cell line ( Miller et al . 2008 ). The aim of the present work is to study anti-tumorigenic actions of curcumin in other rodent endocrine pituitary tumour cells. Moreover, we explored for the first